What is Remedium Bio?
Remedium Bio is a pioneering biotechnology enterprise focused on the development of advanced treatments for large-scale clinical challenges. At the core of its market position is the Prometheus adjustable gene therapy platform, a revolutionary system designed to provide safe, effective, and durable therapeutic gene delivery. Unlike conventional protein-based therapies that often require frequent administration, the Prometheus platform enables simple, post-treatment dose adjustments and remains localized to the site of subcutaneous injection. This technological differentiation offers a high degree of specificity and a cost-effective alternative to existing standards of care. The company's robust pipeline spans high-impact fields, including endocrinology—specifically targeting weight loss and type 2 diabetes—as well as immunology, neurology, and musculoskeletal diseases.
How much funding has Remedium Bio raised?
Remedium Bio has raised a total of $13.8M across 3 funding rounds:
Angel/Seed
$2.3M
Stock/Share Issuance
$1.5M
Series A
$10M
Angel/Seed (2022): $2.3M with participation from Angel Star Ventures, Primo Medical Group, Sherwood Ventures, and Longevitytech.Fund
Stock/Share Issuance (2026): $1.5M, investors not publicly disclosed
Series A (2026): $10M supported by Lifespan Vision Ventures, HKX Capital, and Lilly
Key Investors in Remedium Bio
Lifespan Vision Ventures
A venture firm specializing in longevity and aging reversal, focusing on diagnostics and therapeutics that extend the human healthspan.
HKX Capital
A strategic investment firm that connects capital providers with high-growth ventures to facilitate financial expansion and market entry.
Lilly
A global biopharmaceutical leader dedicated to research-driven innovation in diabetes, oncology, immunology, and neuroscience.
What's next for Remedium Bio?
With the successful closure of this major strategic investment, Remedium Bio is poised to scale its clinical development programs significantly. The focus will likely shift toward advancing its lead candidates through rigorous regulatory pathways and expanding the utility of the Prometheus platform. By replacing traditional, high-cost protein treatments with a single-injection, adjustable gene therapy, the company is strategically positioned to capture significant market share in the endocrinology and chronic disease sectors. Future growth will be defined by the company's ability to demonstrate unprecedented efficacy in human trials while maintaining its commitment to safety and localized therapeutic delivery. As the firm matures, it will likely seek further partnerships with global biopharmaceutical leaders to facilitate the commercialization and global distribution of its innovative pipeline.
See full Remedium Bio company page
